| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 402.8 | 519.4 | 380.4 |
| Other income | 1.8 | 6.6 | 1.0 |
| Total income | 404.6 | 526.0 | 381.4 |
| Profit before exceptional items & tax | -18.8 | 55.4 | -30.4 |
| Exceptional items | 8.9 | -47.1 | 0.0 |
| Profit before tax | -9.9 | 8.3 | -30.4 |
| Net profit | -7.4 | 14.4 | -22.4 |
| Operating margin | -2.4% | 1.6% | -8.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +5.90% |
|---|---|
| Operating profit, year on year | +34.40% |
| Operating profit, quarter on quarter | -142.20% |
NSE results filing, NSE: HIKAL. Figures extracted from the filing.
Hikal Ltd: key numbers
- Share price
- ₹217.58
- Market cap
- ₹2,683 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -79.4×Sector 50.4×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 0.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Annual General Meeting
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal Production Started
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Earnings Call Transcript: Key Takeaways
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
- Call
- Guides 15% growth
Hikal Investor Presentation: Key Takeaways
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Earnings Call: Key Takeaways
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.
Hikal Earnings Call: Key Takeaways
Hikal is navigating a difficult recovery phase, masked by a massive ₹47cr impairment and USFDA warning letter at Bangalore. While margins show sequential improvement, the core business remains stagnant and heavily reliant on regulatory resolution.